(1) Industry trends: We target multi-species and small-scale new medications with our services, and we compete differently with our highlighted multi-functional production lines.

(2) Pharmaceutical Achievements: Over the course of more than ten years, our CSO has worked with Pfizer, BMS, DuPont Pharma, and GSK, where he oversaw the creation of scores of ground-breaking medications in the areas of medicinal chemistry, analytical chemistry, synthetic process, and pilot magnification.

(3) Technology diversification: Using our asymmetric synthesis, diversified reaction, continuous flow, and enzyme-catalyzed reaction technologies, we have a variety of methods and modalities to satisfy the requirements of clients at various phases of development. As a result, R&D and production costs are decreased, R&D is improved, pilot tests are prioritised, and production efficiency is focused, optimising costs and lowering energy usage at the product stage.

(4) Flexibility: Our flexible and intelligent design production suites at the Cangzhou facility are all GMP-compliant and can be tailored to each client's project. Each synthesis uses equipment ranging in size from 1kg to 1000kg, including our high potency/cytotoxic API manufacturing suite, rated for OEL 5. Flexibility without sacrificing quality; all quality management systems follow ICH recommendations.

(5) Client-Centric Approach: More than 300 customers have been handled by Ethix, which has won praise from both domestic and international creative pharmaceutical firms. We are still paying attention to the requests of our clients to assemble the tools, processes, and resources necessary to provide continuous, real-time updates and communication.

(6) Advancing Pharmaceutical R&D Services: We target multi-species and small-scale new medications with our services, and we compete differently with our highlighted multi-functional production lines.